Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial por Walter Suárez Carmona | Ene 27, 2025
GLP-1R agonist therapy and vaccine response: Neglected implications por Walter Suárez Carmona | Ene 27, 2025
Refining Insulin on Board with netIOB for Automated Insulin Delivery por Walter Suárez Carmona | Ene 26, 2025
Applying technologies to simplify strategies for exercise in type 1 diabetes por Walter Suárez Carmona | Ene 26, 2025
